Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.35 USD | +0.43% | -4.26% | -21.29% |
Apr. 18 | Sanara Medtech Inc. Announces $55 Million Debt Facility | CI |
Apr. 05 | Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer | MT |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Capitalization 1 | 314.1 | 225.5 | 377.8 | 350.9 | 278.9 | - |
Enterprise Value (EV) 1 | 314.1 | 225.5 | 377.8 | 350.9 | 278.9 | 278.9 |
P/E ratio | -65.7 x | -27.4 x | -45.5 x | -79 x | -147 x | 57.8 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | 9.36 x | 8.24 x | 5.4 x | 3.58 x | - |
EV / Revenue | - | 9.36 x | 8.24 x | 5.4 x | 3.58 x | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 6,294 | 7,632 | 8,304 | 8,538 | 8,623 | - |
Reference price 2 | 49.90 | 29.55 | 45.50 | 41.10 | 32.35 | 32.35 |
Announcement Date | 3/30/21 | 3/30/22 | 3/20/23 | 3/25/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | - | 24.1 | 45.84 | 64.99 | 78 | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | - | -7.376 | -12.23 | -4.215 | -1.6 | 5 |
Operating Margin | - | -30.61% | -26.68% | -6.49% | -2.05% | - |
Earnings before Tax (EBT) 1 | - | -7.994 | -13.94 | -4.44 | -1.8 | - |
Net income 1 | -4.356 | -8 | -7.938 | -4.303 | -1.8 | 4.7 |
Net margin | - | -33.2% | -17.31% | -6.62% | -2.31% | - |
EPS 2 | -0.7600 | -1.080 | -1.000 | -0.5200 | -0.2200 | 0.5600 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/30/21 | 3/30/22 | 3/20/23 | 3/25/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 5.824 | 6.989 | - | 9.671 | 13.04 | 15.32 | 15.52 | 15.75 | 16.02 | 17.69 | 18.5 | 19.2 | 19.8 | 20.5 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -1.854 | -3.412 | - | -3.194 | -3.122 | -3.012 | -1.216 | -1.866 | -0.9067 | -0.226 | -0.5 | -0.6 | -0.4 | - |
Operating Margin | -31.83% | -48.83% | - | -33.03% | -23.94% | -19.66% | -7.84% | -11.85% | -5.66% | -1.28% | -2.7% | -3.12% | -2.02% | - |
Earnings before Tax (EBT) 1 | -2.048 | -3.557 | - | -3.258 | -3.232 | -4.163 | -1.216 | -1.866 | -1.095 | -0.2624 | -0.6 | -0.7 | -0.4 | -0.1 |
Net income 1 | -2.02 | -3.626 | -3.129 | -3.245 | -1.47 | -4.107 | -1.178 | -1.828 | -1.06 | -0.2372 | -0.6 | -0.7 | -0.4 | -0.1 |
Net margin | -34.69% | -51.88% | - | -33.56% | -11.27% | -26.82% | -7.59% | -11.6% | -6.62% | -1.34% | -3.24% | -3.65% | -2.02% | -0.49% |
EPS 2 | -0.2700 | -0.4800 | -0.4100 | -0.4200 | -0.1800 | -0.5100 | -0.1400 | -0.2200 | -0.1300 | -0.0300 | -0.0700 | -0.0800 | -0.0500 | -0.0100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/21 | 3/30/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/20/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/25/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | 0.17 | - | - | - | - |
Capex / Sales | - | 0.71% | - | - | - | - |
Announcement Date | 3/30/21 | 3/30/22 | 3/20/23 | 3/25/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.29% | 279M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- SMTI Stock
- Financials Sanara MedTech Inc.